{"id":"W2164777416","doi":"10.1016/s1470-2045(15)00041-8","title":"Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Bevacizumab; Capecitabine; Clinical endpoint; Neoadjuvant therapy; Internal medicine; Oncology; Breast cancer; Gemcitabine; Cyclophosphamide; Taxane; Chemotherapy; Surgery; Cancer; Clinical trial; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001190733,0.0003669865,0.002163175,0.00008665901,0.00008013962,0.00001102301,0.0004896784,0.0003322821,0.00006831649],"category_scores_gemma":[0.0002520292,0.0002329369,0.0002946027,0.0001453531,0.0004298362,0.00001034449,0.0002406475,0.0003228649,0.0000120747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004883116,"about_ca_system_score_gemma":0.00177325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001047691,"about_ca_topic_score_gemma":0.002356128,"domain_scores_codex":[0.9971104,0.0008120251,0.000774055,0.000474297,0.0002283829,0.0006008581],"domain_scores_gemma":[0.9981978,0.0003312064,0.000528262,0.0005867935,0.0002158202,0.0001400951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9604034,0.001214312,0.003173948,0.00001823457,0.00117671,0.00006410675,0.001562065,0.00008747054,0.002388564,0.00004524224,0.004647237,0.02521867],"study_design_scores_gemma":[0.9663461,0.002957489,0.01552513,0.00001968942,0.0003370225,0.00007546927,0.0004890618,0.00004581562,0.0009419956,0.000150648,0.01284702,0.000264534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807934,0.002860694,0.00004114325,0.008409084,0.001194677,0.002595488,0.0003439007,0.0000265041,0.003735108],"genre_scores_gemma":[0.9950592,0.0005417176,0.0001380546,0.001228388,0.001014698,0.001689855,0.00005200928,0.00003448385,0.0002416021],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02495414,"threshold_uncertainty_score":0.9498893,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0375631773273734,"score_gpt":0.3579532375713889,"score_spread":0.3203900602440155,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}